ASND — Ascendis Pharma A/S
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1612042 ·
Denmark
Last close
$223.29
Market Cap
$14.64B
52W High
$250.74
52W Low
$203.80
ADV30
599,742
Next earnings
2026-04-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 246,601,000 | 229,086,000 | 24,812,000 | 629,339,000 | 2,003,279,000 | 572,820,000 | 1,515,306,000 |
| Dec 2025 | 247,500,000 | 223,902,000 | 6,442,000 | -33,562,000 | 1,302,570,000 | 616,041,000 | 1,465,391,000 |
| Sep 2025 | 213,634,000 | 191,280,000 | 10,997,000 | -60,989,000 | 1,154,750,000 | 539,092,000 | 1,328,825,000 |
| Jun 2025 | 158,045,000 | 126,598,000 | -52,951,000 | -38,855,000 | 1,087,902,000 | 494,046,000 | 1,275,474,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$60,489,000
Investing CF
$-14,535,000
Financing CF
$17,519,000
CapEx
$-8,485,000
Dividends Paid
—
Buybacks
$-51,857,000
EPS Diluted TTM
$7.38
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
—
Inventory
$314,342,000
Receivables
$196,607,000
ST Investments
—
EBIT TTM
$-26,729,000
Pretax Income TTM
$-167,261,000
Interest Exp TTM
$140,532,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$865,779,008
EBITDA
$-10,224,000
Free Cash Flow
$118,230,128
Enterprise Value
$14,192,742,400
Total Cash
$572,819,968
Total Debt
$896,664,000
Shares Out
65,576,126
Trailing EPS
$8.76
Book Value
$9.12
ROE
332.7%
ROA
-0.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 720,132,000 | -136,271,000 | -228,034,000 | 1,302,570,000 | 1,465,391,000 | — | 53,897,000 |
| Dec 2024 | 363,641,000 | -278,763,000 | -378,084,000 | 1,179,495,000 | 1,285,201,000 | — | -306,197,000 |
| Dec 2023 | 266,718,000 | -455,541,000 | -481,447,000 | 825,587,000 | 971,284,000 | — | -467,361,000 |
| Dec 2022 | 51,174,000 | -561,814,000 | -583,194,000 | 1,089,738,000 | 826,390,000 | — | -495,699,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$10.93
Max Pain — expiry 2026-07-17
max pain strike: $220.00 · spot: $231.20 · call oi: 6,011 · put oi: 607
Expected Move to 2026-07-17:
±$22.00
(9.52%) —
implied range
$209.20 –
$253.20
· ATM straddle on $230.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals plc | $14.47B | $230.59 | — |
| GMAB | GENMAB A/S | $15.09B | $24.58 | — |
| GNMSF | GENMAB A/S | $15.29B | $249.00 | — |
| BBIO | BridgeBio Pharma, Inc. | $13.32B | $68.00 | — |
| AXSM | Axsome Therapeutics, Inc. | $13.04B | $253.40 | — |
News headlines (Yahoo Finance, 1h cache)
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
2026-06-13 20:00 · Yahoo
European Equities Traded in the US as American Depositary Receipts Increase in Friday Trading; Rise for Week
2026-06-12 15:14 · Yahoo
Ascendis Pharma Says TransCon PTH Shows Sustained Efficacy at 5 Years
2026-06-11 20:35 · Yahoo
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
2026-06-11 20:01 · Yahoo
Ascendis Pharma (ASND):10 Most Profitable Growth Stocks to Buy
2026-06-09 23:22 · Yahoo
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
2026-06-08 20:59 · Yahoo
Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Weakness
2026-06-08 16:10 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week
2026-05-29 15:11 · Yahoo
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside
2026-05-28 20:27 · Yahoo
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
2026-05-26 15:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.